Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Above 50-Day Moving Average – Time to Sell?

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$15.00 and traded as high as C$17.00. Fennec Pharmaceuticals shares last traded at C$17.00, with a volume of 604 shares traded.

Fennec Pharmaceuticals Price Performance

The stock has a market capitalization of C$596.14 million, a P/E ratio of -141.67 and a beta of 3.55. The stock has a 50 day moving average price of C$15.09 and a 200-day moving average price of C$12.31.

Insiders Place Their Bets

In related news, Director Rostislav Christov Raykov sold 9,747 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of C$13.23, for a total value of C$128,952.81. Following the transaction, the director owned 2,746,104 shares in the company, valued at C$36,330,955.92. The trade was a 0.35% decrease in their position. Also, insider Robert Christopher Andrade sold 106,844 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the sale, the insider owned 217,675 shares in the company, valued at approximately C$3,619,935.25. The trade was a 32.92% decrease in their position. Insiders own 16.20% of the company’s stock.

Institutional Trading of Fennec Pharmaceuticals

An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in Fennec Pharmaceuticals Inc. (TSE:FRX) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 15.23% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.